Combination therapy with STING agonists and AKT1 inhibitors, as proposed, may disrupt this loop and enhance immune responses, offering a promising approach to address endocrine resistance in ER+HER2– breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.